Trials / Terminated
TerminatedNCT04339595
Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis
A Phase IV Interventional Study to Assess the Disease-Modifying Effect of Long-Term Treatment With Tildrakizumab in Adult Patients With Moderate-To-Severe Plaque Psoriasis (MODIFY)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory biomarkers and its correlation disease relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tildrakizumab | Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first. |
Timeline
- Start date
- 2020-01-29
- Primary completion
- 2020-07-31
- Completion
- 2020-07-31
- First posted
- 2020-04-09
- Last updated
- 2021-12-08
Locations
3 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT04339595. Inclusion in this directory is not an endorsement.